| Hypertensive disease
Benicar vs Qbrelis
Side-by-side clinical, coverage, and cost comparison for hypertensive disease.Deep comparison between: Benicar vs Qbrelis with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsQbrelis has a higher rate of injection site reactions vs Benicar based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Qbrelis but not Benicar, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Benicar
Qbrelis
At A Glance
Oral
Daily
Angiotensin II receptor antagonist
Oral
Once daily
ACE inhibitor
Indications
- Hypertensive disease
- Hypertensive disease
- Heart Failure, Systolic
- Acute myocardial infarction
Dosing
Hypertensive disease (Adults) Starting dose 20 mg once daily; may increase to 40 mg once daily after 2 weeks if further blood pressure reduction needed; oral.
Hypertensive disease (Pediatric, 6 years and older) 10 mg once daily for patients weighing 20 to <35 kg; 20 mg once daily for patients weighing >=35 kg; oral tablet or extemporaneous suspension.
Hypertensive disease Adults: initial 10 mg once daily (5 mg once daily if on diuretics), titrate to 20-40 mg once daily; pediatric patients >=6 years with GFR >30 mL/min/1.73m2: initial 0.07 mg/kg (up to 5 mg) once daily, maximum 0.61 mg/kg (up to 40 mg) once daily, oral.
Heart Failure, Systolic Initial 5 mg once daily (2.5 mg once daily if hyponatremia present) with diuretics and digitalis; increase as tolerated to 40 mg once daily, oral.
Acute myocardial infarction 5 mg within 24 hours of onset, then 5 mg at 24 hours, then 10 mg once daily for at least 6 weeks; initiate at 2.5 mg once daily if systolic BP <=120 mmHg, oral.
Contraindications
- Co-administration of aliskiren in patients with diabetes
- History of angioedema or hypersensitivity related to previous ACE inhibitor treatment
- Hereditary or idiopathic angioedema
- Co-administration of aliskiren in patients with diabetes
- Combination with a neprilysin inhibitor (e.g., sacubitril); do not administer within 36 hours of switching to or from sacubitril/valsartan
Adverse Reactions
Most common (>1%) Dizziness
Postmarketing Asthenia, angioedema, anaphylactic reactions, vomiting, sprue-like enteropathy, hyperkalemia, rhabdomyolysis, acute renal failure, increased blood creatinine levels, alopecia, pruritus, urticaria
Most common (>=2%) Hypertension: headache, dizziness, cough; Heart Failure: hypotension, chest pain; Acute MI: hypotension.
Serious Bone marrow depression, hemolytic anemia, leukopenia/neutropenia, thrombocytopenia, toxic epidermal necrolysis, Stevens-Johnson syndrome, pancreatitis, hyperkalemia, renal dysfunction.
Postmarketing Hyponatremia, hypoglycemia in diabetic patients, mood alterations, mental confusion, hallucinations, psoriasis.
Pharmacology
Olmesartan medoxomil is a selective AT1 subtype angiotensin II receptor antagonist that blocks vasoconstrictor effects of angiotensin II by selectively blocking its binding to the AT1 receptor in vascular smooth muscle, acting independently of angiotensin II synthesis pathways.
ACE inhibitor; lisinopril inhibits angiotensin-converting enzyme, reducing conversion of angiotensin I to angiotensin II, thereby decreasing vasopressor activity and aldosterone secretion to lower blood pressure in hypertension, heart failure, and post-myocardial infarction.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Benicar
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (0/12) · Qty limit (1/12)
Qbrelis
- Covered on 5 commercial plans
- PA (5/12) · Step Therapy (0/12) · Qty limit (9/12)
UnitedHealthcare
Benicar
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (1/8)
Qbrelis
- Covered on 4 commercial plans
- PA (4/8) · Step Therapy (0/8) · Qty limit (1/8)
Humana
Benicar
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Qbrelis
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (1/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Benicar.
No savings programs available for Qbrelis.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
BenicarView full Benicar profile
QbrelisView full Qbrelis profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.